Drugs / Neoadjuvant therapy with PD-L1 inhibitor
Neoadjuvant therapy with PD-L1 inhibitor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05371197 | May 2022 → Jun 2024 | colorectal cancer | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoadjuvant therapy with PD-L1 inhibitor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05371197 ↗ |
| Modality | Monoclonal antibody | “anti-PD-L1 monoclonal antibody (Envafolimab)” NCT05371197 ↗ |